121 related articles for article (PubMed ID: 32051393)
21. MMPs-related risk model identification and SAA1 promotes clear cell renal cell carcinoma migration via ERK-AP1-MMPs axis.
Wei H; Li Y; Zhang J; Xu C; Wei D; Quan C; Zhu S
Sci Rep; 2024 Apr; 14(1):9411. PubMed ID: 38658579
[TBL] [Abstract][Full Text] [Related]
22. Nuclear and cytosolic pS727-STAT3 levels correlate with overall survival of patients affected by clear cell renal cell carcinoma (ccRCC).
Arévalo J; Lorente D; Trilla E; Salcedo MT; Morote J; Meseguer A
Sci Rep; 2021 Mar; 11(1):6957. PubMed ID: 33772065
[TBL] [Abstract][Full Text] [Related]
23. Molecular and Functional Analysis of Sunitinib-Resistance Induction in Human Renal Cell Carcinoma Cells.
Rausch M; Rutz A; Allard PM; Delucinge-Vivier C; Docquier M; Dormond O; Wolfender JL; Nowak-Sliwinska P
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34208775
[TBL] [Abstract][Full Text] [Related]
24. Hypoxia-induced PLOD2 promotes clear cell renal cell carcinoma progression via modulating EGFR-dependent AKT pathway activation.
Liu T; Xiang W; Chen Z; Wang G; Cao R; Zhou F; Meng Z; Luo Y; Chen L
Cell Death Dis; 2023 Nov; 14(11):774. PubMed ID: 38008826
[TBL] [Abstract][Full Text] [Related]
25. The novel CDK9 inhibitor, XPW1, alone and in combination with BRD4 inhibitor JQ1, for the treatment of clear cell renal cell carcinoma.
Kuang Z; Guo K; Cao Y; Jiang M; Wang C; Wu Q; Hu G; Ao M; Huang M; Qin J; Zhao T; Lu S; Sun C; Li M; Wu T; Liu W; Fang M
Br J Cancer; 2023 Dec; 129(12):1915-1929. PubMed ID: 37884683
[TBL] [Abstract][Full Text] [Related]
26. SCGN and STAT3 expressions are associated with the prognosis of ccRCC.
Lai C; Gong J; Tang J; Liu Q; Zhang M; Lai M; Zhang D; Teng X
Pathol Res Pract; 2023 Dec; 252():154940. PubMed ID: 37977033
[TBL] [Abstract][Full Text] [Related]
27. ARRDC3 regulates the targeted therapy sensitivity of clear cell renal cell carcinoma by promoting AXL degradation.
Chen M; Yin B; Liu Y; Li M; Shen S; Wu J; Li W; Fan J
Cell Cycle; 2024 Jan; 23(1):56-69. PubMed ID: 38389126
[TBL] [Abstract][Full Text] [Related]
28. Side population analysis in clear cell renal cell carcinoma.
Huang R; Meens J; Yuzwa S; Ailles L; Ohh M; Robinson CM
Biochem Biophys Res Commun; 2021 Dec; 585():196-202. PubMed ID: 34813980
[TBL] [Abstract][Full Text] [Related]
29. Discovery of a small-molecule binder of the oncoprotein gankyrin that modulates gankyrin activity in the cell.
Chattopadhyay A; O'Connor CJ; Zhang F; Galvagnion C; Galloway WR; Tan YS; Stokes JE; Rahman T; Verma C; Spring DR; Itzhaki LS
Sci Rep; 2016 Apr; 6():23732. PubMed ID: 27046077
[TBL] [Abstract][Full Text] [Related]
30. How should clinicians address intratumour heterogeneity in clear cell renal cell carcinoma?
Soultati A; Stares M; Swanton C; Larkin J; Turajlic S
Curr Opin Urol; 2015 Sep; 25(5):358-66. PubMed ID: 26125509
[TBL] [Abstract][Full Text] [Related]
31. Aldolase B attenuates clear cell renal cell carcinoma progression by inhibiting CtBP2.
Tan M; Pan Q; Wu Q; Li J; Wang J
Front Med; 2023 Jun; 17(3):503-517. PubMed ID: 36790589
[TBL] [Abstract][Full Text] [Related]
32. NNT-induced tumor cell "slimming" reverses the pro-carcinogenesis effect of HIF2a in tumors.
Xiong Z; Xiong W; Xiao W; Yuan C; Shi J; Huang Y; Wang C; Meng X; Chen Z; Yang H; Chen K; Zhang X
Clin Transl Med; 2021 Jan; 11(1):e264. PubMed ID: 33463050
[TBL] [Abstract][Full Text] [Related]
33. IL1R2 promotes tumor progression via JAK2/STAT3 pathway in human clear cell renal cell carcinoma.
Liu Y; Xing Z; Yuan M; Xu B; Chen L; Zhang D; Zhou Y; Huang H; Zheng X; Zhang J; Jiang J
Pathol Res Pract; 2022 Oct; 238():154069. PubMed ID: 36029680
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and evaluation of 2,5-substituted pyrimidines as small-molecule gankyrin binders.
Kanabar D; Kane EI; Chavan T; Laflamme TM; Suarez E; Goyal M; Gupta V; Spratt DE; Muth A
Future Med Chem; 2024 Feb; 16(3):239-251. PubMed ID: 38205637
[No Abstract] [Full Text] [Related]
35. CDCA5-EEF1A1 interaction promotes progression of clear cell renal cell carcinoma by regulating mTOR signaling.
Wang X; Shi A; Liu J; Kong W; Huang Y; Xue W; Yang F; Huang J
Cancer Cell Int; 2024 Apr; 24(1):147. PubMed ID: 38658931
[TBL] [Abstract][Full Text] [Related]
36. Small-Molecule Gankyrin Inhibition as a Therapeutic Strategy for Breast and Lung Cancer.
Kanabar D; Goyal M; Kane EI; Chavan T; Kabir A; Wang X; Shukla S; Almasri J; Goswami S; Osman G; Kokolis M; Spratt DE; Gupta V; Muth A
J Med Chem; 2022 Jul; 65(13):8975-8997. PubMed ID: 35758870
[TBL] [Abstract][Full Text] [Related]
37. SUV39H1 deficiency suppresses clear cell renal cell carcinoma growth by inducing ferroptosis.
Wang J; Yin X; He W; Xue W; Zhang J; Huang Y
Acta Pharm Sin B; 2021 Feb; 11(2):406-419. PubMed ID: 33643820
[TBL] [Abstract][Full Text] [Related]
38. Downregulation of praja2 restrains endocytosis and boosts tyrosine kinase receptors in kidney cancer.
Rinaldi L; Chiuso F; Senatore E; Borzacchiello D; Lignitto L; Iannucci R; Donne RD; Fuggi M; Reale C; Russo F; Russo NA; Giurato G; Rizzo F; Sellitto A; Santangelo M; De Biase D; Paciello O; D'Ambrosio C; Amente S; Garbi C; Dalla E; Scaloni A; Weisz A; Ambrosino C; Insabato L; Feliciello A
Commun Biol; 2024 Feb; 7(1):208. PubMed ID: 38379085
[TBL] [Abstract][Full Text] [Related]
39. LMX1B-associated gankyrin expression predicts poor prognosis in glioma patients.
Guo X; Piao H; Xue Y; Liu Y; Zhao H
J Int Med Res; 2020 Sep; 48(9):300060520954764. PubMed ID: 32960116
[TBL] [Abstract][Full Text] [Related]
40. The study of pH-dependent stability shows that the TPLH-mediated hydrogen-bonding network is important for the conformation and stability of human gankyrin.
Yuan C; Guo Y; Zhu L; Guo W; Mahajan A; Weghorst CM; Li J
Biochemistry; 2013 Jul; 52(28):4848-57. PubMed ID: 23777370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
